Compare · AXDX vs WAT
AXDX vs WAT
Side-by-side comparison of Accelerate Diagnostics Inc. (AXDX) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXDX and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $19.34B, about 98.1x AXDX ($197.2M).
- Over the past year, AXDX is down 93.2% and WAT is down 8.9% - WAT leads by 84.3 points.
- WAT has hit the wire 8 times in the past 4 weeks while AXDX has been quiet.
- WAT has more recent analyst coverage (25 ratings vs 1 for AXDX).
- Company
- Accelerate Diagnostics Inc.
- Waters Corporation
- Price
- $0.14+59.82%
- $309.80-0.45%
- Market cap
- $197.2M
- $19.34B
- 1M return
- -93.21%
- +2.49%
- 1Y return
- -93.21%
- -8.90%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1995
- News (4w)
- 0
- 8
- Recent ratings
- 1
- 25
Accelerate Diagnostics Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest AXDX
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
- SEC Form 3 filed by new insider Shalhoub Paul Vincent
- Amendment: SEC Form 10-K/A filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)
Latest WAT
- Amendment: SEC Form SCHEDULE 13G/A filed by Waters Corporation
- Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
- Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
- SEC Form DEFA14A filed by Waters Corporation
- SEC Form DEF 14A filed by Waters Corporation
- Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
- SEC Form 4 filed by Bennett Jianqing
- Waters upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Jiang Wei
- SEC Form 4 filed by Knight Heather